Drugs / Medicago Sativa
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05723458 | Jul 2023 → Jan 2024 | osteoarthritis, knee | Tabriz University of Medical Sciences | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03714438 | Feb 2017 → Jan 2018 | glucose intolerance | University of Guadalajara | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Medicago Sativa | “The present double-blind, randomized and placebo-controlled study will be conducted on patients with knee osteoarthritis to evaluate the safety and efficacy of a combined cream...” NCT05723458 ↗ |
| Route | Oral | “Single oral doses of Medicago sativa (1,500 mg), 30 min before before the oral glucose tolerance test.” NCT03714438 ↗ |